Clinical evaluation of a spasmolytic drug, dimidin
Trusov, V.V.; Pimenóv, L.T.; Guseva, L.P.
Vrachebnoe Delo 8: 30-34
1975
ISSN/ISBN: 0049-6804 PMID: 1221600 Document Number: 87137
Document emailed within 1 workday
Related Documents
Frimodt-Moller, C.; Hald, T.; Folkenborg, O. 1973: A controlled clinical trial of a new bladder spasmolytic drug--Urispadol Ugeskrift for Laeger 135(43): 2321-2324Laudi, M.; Fontana, G. 1979: Clinical evaluation of a new synthetic spasmolytic (rociverine) in the urological field Il Farmaco; Edizione Pratica 34(12): 553-560
Zwagemakers, J.M.; Claassen, V. 1980: Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 1: Antimuscarinic and spasmolytic effects Arzneimittel-Forschung 30(9): 1517-1526
Fontaine, L.; Grand, M.; Molho, D.; Boschetti, E. 1968: Spasmolytic activity of 4-methylumbelliferone on Oddi's sphincter. Studies on the mode of action of the drug Therapie 23(1): 63-74
Mehta, R.K.; Link, R.P. 1974: Evaluation of spasmolytic activity of SK and F 21000 on uterine smooth muscle preparations Indian Journal of Experimental Biology 12(1): 15-17
Cockburn, I. 1986: Cyclosporine A: a clinical evaluation of drug interactions Transplantation Proceedings 18(6 Suppl 5: 50-55
Siest, G.; Delwaide, P.; Malya, P.A.G.; Breuer, H.; Galteau, M.M.; Salway, J.G.; Tognoni, G.; Tryding, N. 1988: International Federation of Clinical Chemistry, Scientific Committee: Drug interferences and drug effects in clinical chemistry. Part 6. Laboratory tests in monitoring drug administration Journal of Clinical Chemistry and Clinical Biochemistry 26(3): 181-186
Arteaga, A.; Foradori, A.; Eyzaguirre, J.; Lira, P.; Vasquez, A.; Soto, S.; Alliende, M.E.; Guzman, L. 1970: Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia Revista Medica de Chile 98(10): 689-694
Fracassi, M.U.; Delvecchio, F.R. 1971: A new antipsychotic drug: pimozide R 6238. Clinical evaluation Prensa Medica Argentina 58(28): 1444-1449
Osieka, R. 1984: Human malignant melanoma: preclinical and clinical drug evaluation Behring Institute Mitteilungen 74: 353-367
Zanasi, R.; Volonteri, G.; Castaldi, D. 1971: Clinical evaluation of the use in arthrosis of a drug with antirheumatic and anti-inflammatory action Minerva Medica 62(3): 174-178
Bolińska, H.; Kaluzna, J. 1970: Clinical evaluation of irrigor as a drug improving the coronary blood flow Wiadomosci Lekarskie 23(17): 1491-1493
Liu, J.; Zang, Y.-z.; Xie, W.-m. 2010: Combined drug therapy clinical evaluation of laryngopharyngeal reflux diseases Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 45(3): 244-246
Taniguchi, K.; Nakamura, S.; Iesaka, Y.; Nitta, M.; Ito, H.; Kirigaya, H.; Takeuchi, J.; Fujiwara, H.; Iizumi, T.; Inada, M. 1985: Clinical evaluation of urapidil, a new antihypertensive drug: preliminary findings in Japan Clinical Therapeutics 7(5): 559-567
Shaikh, A.S.; Li, Y.; Cao, L.; Guo, R. 2018: Analysis of phenytoin drug concentration for evaluation of clinical response, uncontrolled seizures and toxicity Pakistan Journal of Pharmaceutical Sciences 31(4(Special): 1697-1700
Sun, B. 1997: Current progress of clinical trials for new drug evaluation in neonatal and pediatric clinics in China Zhongguo Yao Li Xue Bao 18(6): 537-539
Okawa, T.; Kita, M. 1988: Clinical evaluation of implantable drug delivery system (Port-A-Cath) in cancer chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(8 Part 2): 2659-2663
Nishikaze, O. 1975: Drug-drug interaction and drug-induced interference with clinical laboratory test procedures--chairman's introductory remarks Rinsho Byori. Japanese Journal of Clinical Pathology 23(2): 75
Zaka-Ur-Rehman, Z.; Jamshaid, M.; Chaudhry, A. 2008: Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients Pakistan Journal of Pharmaceutical Sciences 21(2): 185-194
Tassinari, M.C.; Gualandi, M.; Guerra, G.; Barbieri, D.; Benassi, N.; Lazzarato, M.; Dallara, G.; Gallerani, M. 1986: Occurrence of HTLV-IIi infection and related clinical forms in a homogeneous group of drug addicts. Significance of immunologic changes and evaluation of risk factors Recenti Progressi in Medicina 77(10): 461-465